# A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

> **NCT02625389** · PHASE4 · COMPLETED · sponsor: **Guerbet** · enrollment: 132 (actual)

## Conditions studied

- Congenital Hemangioma
- Hemangioendothelioma
- Angiosarcoma
- Arteriovenous Malformations

## Interventions

- **DRUG:** Lipiodol Ultra Fluid with surgical glues

## Key facts

- **NCT ID:** NCT02625389
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2021-05-12
- **Final completion:** 2021-05-12
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625389, "A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02625389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*